BioSpace News Archive

ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent, product-specific J-code for ASCENIV™.

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the completion of its previously announced underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results in vision loss and blindness.

ICP monitoring devices, or intracranial pressure (ICP) monitoring devices, are placed inside the head to monitor the pressure inside the skull and transmit measurements or data to a recording device

Dante Labs has already analysed two million and a half COVID-19 RT-PCR tests and sequenced more than 30,000 human whole genomes thanks to its Immensa™ Genome Platform

Maypharm announces new botulinum toxin, METOX on January 26, 2021.

Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, “events”) in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced.

Rhythm Pharmaceuticals announces Clinical data from Phase 2 Basket Study including five cohorts totaling 65 patients demonstrated proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, SRC1 and SH2B1 deficiency obesities – -- Phase 2 Basket Study responder rates and updated sequencing results suggest 100,000-200,000 potentially setmelanotide-responsive HET POMC, PCSK1 or LEPR deficiencies and SRC1 or SH2B1 deficiency obesity patients in U.S. --

Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on employing Metered Dose Inhaler (MDI) technology to deliver non-psychoactive cannabinoid compounds, announced today that it has hired Dr. Duane Drinkwine, Ph.D., to oversee all laboratory operations for the Company.

Innova Medical Group, Inc., the world’s largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced that the company has officially started INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test kit production in its new facilities in Southern California.